Stacey E. Rudd

542 total citations
20 papers, 409 citations indexed

About

Stacey E. Rudd is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Stacey E. Rudd has authored 20 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Stacey E. Rudd's work include Radiopharmaceutical Chemistry and Applications (13 papers), Medical Imaging Techniques and Applications (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Stacey E. Rudd is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (13 papers), Medical Imaging Techniques and Applications (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Stacey E. Rudd collaborates with scholars based in Australia, United States and Netherlands. Stacey E. Rudd's co-authors include Paul S. Donnelly, Rodney J. Hicks, Peter Roselt, Carleen Cullinane, Lachlan E. McInnes, Asif Noor, Katherine A. Morgan, Guy Y. Krippner, Xiaowei Wang and Benjamin J. Blyth and has published in prestigious journals such as Chemical Reviews, Angewandte Chemie International Edition and Accounts of Chemical Research.

In The Last Decade

Stacey E. Rudd

19 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stacey E. Rudd Australia	11	285	159	126	90	36	20	409
Karolin Pohle Germany	11	298 1.0×	176 1.1×	129 1.0×	65 0.7×	39 1.1×	12	484
Gemma Dias United Kingdom	11	194 0.7×	147 0.9×	116 0.9×	50 0.6×	51 1.4×	21	347
Drishty Satpati India	12	318 1.1×	186 1.2×	91 0.7×	112 1.2×	43 1.2×	50	428
Louis Allott United Kingdom	11	306 1.1×	145 0.9×	89 0.7×	87 1.0×	57 1.6×	28	420
Mai Lin United States	14	307 1.1×	108 0.7×	69 0.5×	112 1.2×	26 0.7×	24	437
Cindy R. Fischer Switzerland	11	287 1.0×	125 0.8×	96 0.8×	99 1.1×	102 2.8×	14	491
Roger M. Bjerke Norway	12	448 1.6×	166 1.0×	79 0.6×	282 3.1×	22 0.6×	29	600
Pauline Désogère United States	12	106 0.4×	115 0.7×	76 0.6×	124 1.4×	28 0.8×	20	413
Kwon Joong Yong United States	11	360 1.3×	132 0.8×	158 1.3×	211 2.3×	17 0.5×	12	548
Elisa Garcı́a Garayoa Switzerland	11	369 1.3×	318 2.0×	138 1.1×	93 1.0×	60 1.7×	14	543

Countries citing papers authored by Stacey E. Rudd

Since Specialization

Citations

This map shows the geographic impact of Stacey E. Rudd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stacey E. Rudd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stacey E. Rudd more than expected).

Fields of papers citing papers by Stacey E. Rudd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stacey E. Rudd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stacey E. Rudd. The network helps show where Stacey E. Rudd may publish in the future.

Co-authorship network of co-authors of Stacey E. Rudd

This figure shows the co-authorship network connecting the top 25 collaborators of Stacey E. Rudd. A scholar is included among the top collaborators of Stacey E. Rudd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stacey E. Rudd. Stacey E. Rudd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Rudd, Stacey E., et al.. (2025). Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab. Chemical Science. 16(9). 3998–4005. 5 indexed citations

2.

Gehlsen, Kurt R., et al.. (2025). Abstract B005: Copper-67 based targeted radioligand therapy to the somatostatin receptor 2 (SSTR2) provides added efficacy and may prime small cell lung cancer for immunotherapy. Clinical Cancer Research. 31(2_Supplement). B005–B005. 1 indexed citations

3.

Rudd, Stacey E., Asif Noor, Katherine A. Morgan, & Paul S. Donnelly. (2024). Diagnostic Positron Emission Tomography Imaging with Zirconium-89 Desferrioxamine B Squaramide: From Bench to Bedside. Accounts of Chemical Research. 57(9). 1421–1433. 4 indexed citations

4.

Wichmann, Christian, Peter Roselt, Stacey E. Rudd, et al.. (2023). Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo. Nuclear Medicine and Biology. 120-121. 108351–108351. 9 indexed citations

5.

Hegi‐Johnson, Fiona, Stacey E. Rudd, Christian Wichmann, et al.. (2023). PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study. International Journal of Radiation Oncology*Biology*Physics. 117(3). 675–682. 10 indexed citations

6.

Morgan, Katherine A., Stacey E. Rudd, Asif Noor, & Paul S. Donnelly. (2023). Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides. Chemical Reviews. 123(20). 12004–12035. 55 indexed citations

7.

Hegi‐Johnson, Fiona, Stacey E. Rudd, Christian Wichmann, et al.. (2022). ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with ⁸⁹ Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ Open. 12(11). e056708–e056708. 15 indexed citations

8.

Hegi‐Johnson, Fiona, Stacey E. Rudd, Rodney J. Hicks, et al.. (2022). Imaging immunity in patients with cancer using positron emission tomography. npj Precision Oncology. 6(1). 24–24. 22 indexed citations

9.

Wichmann, Christian, Peter Roselt, Stacey E. Rudd, et al.. (2021). AUTOMATED RADIOSYNTHESIS OF [(89)ZR]ZR-DFOSQ-DURVALUMAB ON THE IPHASE MULTISYN MODULE. Internal Medicine Journal. 51. 1206–1206. 3 indexed citations

10.

Liapis, Vasilios, William Tieu, Tessa Gargett, et al.. (2021). Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models. Molecular Imaging and Biology. 23(6). 914–928. 6 indexed citations

11.

Noor, Asif, Stacey E. Rudd, Peter Roselt, et al.. (2021). Imaging Somatostatin Positive Tumors with Tyr³-Octreotate/Octreotide Conjugated to Desferrioxamine B Squaramide Radiolabeled with either Zirconium-89 or Gallium-68. Bioconjugate Chemistry. 32(7). 1192–1203. 8 indexed citations

12.

Rudd, Stacey E., Lesley A. Pearce, Carleen Cullinane, et al.. (2021). Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor. Chemical Science. 12(26). 9004–9016. 15 indexed citations

13.

Liapis, Vasilios, William Tieu, Stacey E. Rudd, et al.. (2020). Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®. EJNMMI Radiopharmacy and Chemistry. 5(1). 27–27. 10 indexed citations

14.

Noor, Asif, Stacey E. Rudd, Kelly Waldeck, et al.. (2020). Bivalent Inhibitors of Prostate-Specific Membrane Antigen Conjugated to Desferrioxamine B Squaramide Labeled with Zirconium-89 or Gallium-68 for Diagnostic Imaging of Prostate Cancer. Journal of Medicinal Chemistry. 63(17). 9258–9270. 16 indexed citations

15.

McInnes, Lachlan E., Stacey E. Rudd, & Paul S. Donnelly. (2017). Copper, gallium and zirconium positron emission tomography imaging agents: The importance of metal ion speciation. Coordination Chemistry Reviews. 352. 499–516. 53 indexed citations

16.

Rudd, Stacey E., Peter Roselt, Carleen Cullinane, Rodney J. Hicks, & Paul S. Donnelly. (2016). A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies. Chemical Communications. 52(80). 11889–11892. 86 indexed citations

17.

Burvenich, Ingrid J.G., Fook-Thean Lee, Hui Gan, et al.. (2016). In Vitro and In Vivo Evaluation of ⁸⁹Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy. Theranostics. 6(12). 2225–2234. 18 indexed citations

18.

Alt, Karen, Brett M. Paterson, Erik Westein, et al.. (2015). A Versatile Approach for the Site‐Specific Modification of Recombinant Antibodies Using a Combination of Enzyme‐Mediated Bioconjugation and Click Chemistry. Angewandte Chemie International Edition. 54(26). 7515–7519. 43 indexed citations

19.

Alt, Karen, Brett M. Paterson, Erik Westein, et al.. (2015). A Versatile Approach for the Site‐Specific Modification of Recombinant Antibodies Using a Combination of Enzyme‐Mediated Bioconjugation and Click Chemistry. Angewandte Chemie. 127(26). 7625–7629. 30 indexed citations

20.

Rudd, Stacey E. & George Bárány. (1984). 3-Methyl-2(3H)-benzothiazolone, C8H7NOS. Acta Crystallographica Section C Crystal Structure Communications. 40(12). 2118–2120.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact